



Biotech Daily

Wednesday February 1, 2023

Daily news on ASX-listed biotechnology companies

Actinogen Appoints Dr Dana Hilt CMO

[ACTINOGEN MEDICAL](#)

Actinogen says it has appointed Dr Dana Hilt as chief medical officer with former chief medical officer Prof Paul Rolan continuing as head of clinical pharmacology.

Actinogen said Dr Hilt had more than 25 years of experience in central nervous system drug development.

The company said that most recently, Dr Hilt was Frequency Therapeutics chief medical officer and previously worked for Lysosomal Therapeutics, Guilford Pharmaceuticals, Ascend Pharmaceuticals, Critical Therapeutics and Amgen.

Actinogen said Dr Hilt had a Doctor of Medicine from Boston's Tufts University and held academic positions at the University of Maryland and University of South California.

Actinogen was up 0.2 cents or 2.2 percent to 9.2 cents.